Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.5 EUR | +0.69% | +0.55% | -11.91% |
04-11 | Eurobio Scientific: 2023 results down, share price falls | CF |
01-30 | Eurobio Scientific Société anonyme acquired Alpha Biotech Ltd. | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 30.33 | 51.17 | 191.9 | 292.3 | 220.9 | 147.2 | 147.2 | - |
Enterprise Value (EV) 1 | 43.5 | 62.81 | 156.1 | 205.6 | 243 | 168.3 | 137.3 | 114.3 |
P/E ratio | - | - | - | - | 8.38 x | 38.3 x | 15.2 x | 11.9 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 0.6 x | 0.87 x | 1.02 x | 1.59 x | 1.45 x | 1.29 x | 1.07 x | 0.99 x |
EV / Revenue | 0.86 x | 1.06 x | 0.83 x | 1.12 x | 1.59 x | 1.29 x | 1 x | 0.77 x |
EV / EBITDA | 5.59 x | 8.97 x | 1.77 x | - | 6 x | 6.17 x | 4.72 x | 3.5 x |
EV / FCF | -20.2 x | 18.5 x | 2.97 x | 3.21 x | 6.04 x | 6.22 x | 7.08 x | 4.84 x |
FCF Yield | -4.95% | 5.41% | 33.7% | 31.2% | 16.6% | 16.1% | 14.1% | 20.6% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 9,896 | 10,910 | 11,324 | 10,857 | 10,848 | 10,224 | 10,224 | - |
Reference price 2 | 3.065 | 4.690 | 16.95 | 26.92 | 20.36 | 14.40 | 14.40 | 14.40 |
Announcement Date | 17/04/19 | 14/04/20 | 29/04/21 | 06/04/22 | 05/04/23 | 26/04/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 50.4 | 59.1 | 188.9 | 184.1 | 152.6 | 130 | 138 | 148.4 |
EBITDA 1 | 7.781 | 7 | 88.2 | - | 40.5 | 27.28 | 29.1 | 32.7 |
EBIT 1 | 1.6 | 3.4 | 84 | 72.9 | 30.87 | 22.46 | 25.3 | 28.8 |
Operating Margin | 3.17% | 5.75% | 44.47% | 39.6% | 20.23% | 17.28% | 18.33% | 19.41% |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
Net income 1 | -2.8 | - | 73.5 | - | 24.94 | 4.835 | 9.8 | 11 |
Net margin | -5.56% | - | 38.91% | - | 16.34% | 3.72% | 7.1% | 7.41% |
EPS 2 | - | - | - | - | 2.430 | 0.4300 | 0.9500 | 1.210 |
Free Cash Flow 1 | -2.151 | 3.398 | 52.63 | 64.07 | 40.24 | 25.1 | 19.4 | 23.6 |
FCF margin | -4.27% | 5.75% | 27.86% | 34.8% | 26.37% | 19.22% | 14.06% | 15.9% |
FCF Conversion (EBITDA) | - | 48.54% | 59.68% | - | 99.36% | 91.94% | 66.67% | 72.17% |
FCF Conversion (Net income) | - | - | 71.61% | - | 161.36% | 418.33% | 197.96% | 214.55% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 17/04/19 | 14/04/20 | 29/04/21 | 06/04/22 | 05/04/23 | 26/04/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 13.2 | 11.6 | - | - | 22.1 | 8.8 | - | - |
Net Cash position 1 | - | - | 35.8 | 86.7 | - | - | 9.9 | 32.9 |
Leverage (Debt/EBITDA) | 1.692 x | 1.663 x | - | - | 0.5465 x | 0.3223 x | - | - |
Free Cash Flow 1 | -2.15 | 3.4 | 52.6 | 64.1 | 40.2 | 25.1 | 19.4 | 23.6 |
ROE (net income / shareholders' equity) | - | - | 103% | - | 14.9% | 7.3% | 9.9% | 10.8% |
ROA (Net income/ Total Assets) | - | - | 58% | - | 9.23% | 3.9% | 5.3% | 5.9% |
Assets 1 | - | - | 126.7 | - | 270.3 | 153.8 | 184.9 | 186.4 |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 2.83 | 2.2 | 3 | 3 |
Capex / Sales | - | - | - | - | 1.86% | 1.68% | 2.17% | 2.02% |
Announcement Date | 17/04/19 | 14/04/20 | 29/04/21 | 06/04/22 | 05/04/23 | 26/04/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.91% | 157M | |
+22.10% | 42.68B | |
-2.45% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+8.16% | 24.94B | |
-20.00% | 18.96B | |
+30.08% | 12.3B | |
-2.88% | 11.95B | |
-2.84% | 11.55B |
- Stock Market
- Equities
- ALERS Stock
- Financials Eurobio Scientific